Graupner M, Gutkin B: Modeling nicotinic neuromodulation from global functional and network levels to nAChR based mechanisms. Acta Pharmacol Sin. 2009, 30: 681-693. 10.1038/aps.2009.87.
Marrero MB, Lucas R, Salet C, Hauser TA, Mazurov A, Lippiello PM, Bencherif M: An α7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J Pharmacol Exp Ther. 2010, 332: 173-180. 10.1124/jpet.109.154633.
Kucinski A, Syposs C, Wersinger S, Bencherif M, Stachowiak MK, Stachowiak EK: α7 neuronal nicotinic receptor agonist (TC-7020) reverses increased striatal dopamine release during acoustic PPI testing in a transgenic mouse model of schizophrenia. Schizophr Res. 2012, 136: 82-87. 10.1016/j.schres.2012.01.005.
Zwart R, Vijverberg HP: Potentiation and inhibition of neuronal nicotinic receptors by atropine: competitive and noncompetitive effects. Mol Pharmacol. 1997, 52: 886-895.
Williams DK, Wang J, Papke RL: Investigation of the molecular mechanism of the α7 nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states. Mol Pharmacol. 2011, 80: 1013-1032. 10.1124/mol.111.074302.